

**Full Title:**

**PATIENT FACTORS ASSOCIATED WITH NON-ATTENDANCE OF  
COLONOSCOPY AFTER A POSITIVE SCREENING FAECAL OCCULT  
BLOOD TEST**

**Short title:**

**Non-attendance at colonoscopy after positive FOBt**

**Authors:**

Andrew A Plumb<sup>1</sup>

Alex Ghanouni<sup>2</sup>

Sandra Rainbow<sup>3</sup>

Natasha Djedovic<sup>3</sup>

Sarah Marshall<sup>4</sup>

Judith Stein<sup>5</sup>

Stuart A Taylor<sup>1</sup>

Steve Halligan<sup>1</sup>

Georgios Lyratzopoulos<sup>2</sup>

Christian von Wagner<sup>2</sup>

<sup>1</sup>Centre for Medical Imaging, University College London, 3<sup>rd</sup> Floor East, 250

Euston Rd, London, NW1 2PG

<sup>2</sup>Health Behaviour Research Centre, University College London, 1-19

Torrington Place, London, WC1E 6BT

<sup>3</sup>London Hub, Bowel Cancer Screening Programme, Northwick Park Hospital,  
Watford Rd, Harrow, HA1 3UJ

<sup>4</sup>St Marks Screening Centre, St Marks Hospital, Harrow, HA1 3UJ

<sup>5</sup>University College Screening Centre, University College London Hospitals,  
235 Euston Rd, London, NW1 2BU

**Corresponding author:**

Dr Christian von Wagner

Senior Lecturer in Behavioural Research in Early Diagnosis of Cancer

1-19 Torrington Place

London

WC1E 6BT

[c.wagner@ucl.ac.uk](mailto:c.wagner@ucl.ac.uk)

## **Abstract:**

**Background:** Screening participants with abnormal faecal occult blood test (FOBT) results who do not attend further testing are at high-risk of colorectal cancer (CRC), yet little is known about their reasons for non-attendance.

**Methods:** We conducted a medical record review of 170 patients from two [BLINDED SCREENING PROGRAMME] screening centres who had abnormal gFOBT screening tests between November 2011 and April 2013 and did not undergo colonoscopy. Using information contained in patient records, we coded and categorised reasons for non-attendance.

**Results:** Of the 170 patients, 82 were eligible for review, of which 66 had at least one recorded reason for lack of colonoscopy follow-up. Reasons fell into seven main categories: (i) other commitments, (ii) unwillingness to have the test, (iii) a feeling that the FOBT result was a false-positive, (iv) another health issue taking priority, (v) failing to complete bowel preparation, (vi) practical barriers (e.g. lack of transport), and (vii) having had or planning colonoscopy elsewhere. The most common single reasons were unwillingness to have a colonoscopy and being away.

**Conclusions:** We identify a range of apparent reasons for colonoscopy non-attendance after a positive FOBT screening. Education regarding the interpretation of gFOBT findings, offer of alternative confirmatory test options and flexibility in the timing or location of subsequent testing might decrease non-attendance of diagnostic testing following positive FOBT.

## Introduction

There are many methods of screening for colorectal cancer (CRC), although one common approach is periodic faecal occult blood testing (FOBt)<sup>1,2</sup>. Meta-analysis of randomised trials demonstrates that guaiac-based FOBt reduces CRC-related mortality by approximately 16%<sup>3</sup>. Such mortality reductions require further colonic testing after a positive FOBt to diagnose CRC and treat smaller cancers or adenomas by endoscopic excision. Maximising screening completion (i.e. colonoscopy) is crucial for these patients, because up to 10% will have CRC at their first screen<sup>4</sup>.

Randomised trials of FOBt screening reported non-completion rates of 7-17% after a positive FOBt result<sup>5-8</sup>. Similarly, analysis of the UK CRC screening pilot<sup>9</sup> and during national roll-out<sup>4</sup> found non-completion rates of 15-18% after positive FOBt. Comparable French data report a 12% rate<sup>10</sup>; in Ontario, Canada, the figure is approximately 1 in 3<sup>11</sup>. Therefore, depending on programme structure, 10-33% of FOBt-positive screenees do not undergo confirmatory testing. Certain patient groups are at higher risk of non-completion; for example, those with lower socio-economic status<sup>12, 13</sup>, or physical/psychological co-morbidity<sup>14</sup>. These “epidemiological signals” suggest there may be missed diagnostic opportunities<sup>15</sup> in FOBt-based CRC screening at the time of colonoscopy – which might be targets to improve uptake.

In general terms, missed diagnostic opportunities may be due to organizational factors (e.g. insufficient endoscopy resource, poor referral

guidelines) or patient factors (e.g. cognitive, emotional or physical barriers). For example, physicians commonly fail to act on positive FOBt results<sup>16</sup>, either because they never reviewed the result or chose to repeat the FOBt, thereby going against good practice guidelines<sup>17,18</sup>. However, these individual physician-related and organizational factors are of less relevance to population screening programmes in which endoscopy capacity is assured, referral guidelines are established, and the administrative burden is often centralized<sup>4,10,11</sup>. Conversely, there are few data regarding patient-specific factors underpinning non-completion in this setting. Lower socio-economic status and physical/psychological co-morbidity are associated with higher rates of non-completion, but we do not know how these risk factors translate to individual decision-making.

Thus, FOBt-positive individuals who do not attend for colonoscopy represent a large, high-risk group. There are few patient-level data on why such non-attendance occurs. Therefore, we investigated this in a population-based screening programme with a centralised call-recall system via retrospective review of detailed screening records.

## **Materials and Methods**

This study was conducted within the [BLINDED SCREENING PROGRAMME, ScP] and was approved by the [ScP] Research Committee. Following HRA guidance, ethical permission was not required for retrospective review of anonymised, routinely-acquired data.

## **Study Population**

The [ScP] uses biennial FOBt for individuals aged 60-74 years<sup>4</sup>.

Administration and analysis of FOBt kits is coordinated by 5 regional laboratories. After a positive result, clinical review and colonic testing are conducted at a local “screening centre”. Clinical review is led by a trained Specialist Screening Practitioner (SSP). The screening pathway is shown in Figure 1. This study was conducted within two of the 62 screening centres. These centres were selected because they (a) had resources available to support the study, (b) had pre-existing research collaborations with the study team and (c) were located within a single Hub, simplifying information governance.

Individuals were eligible for inclusion if they had a positive FOBt result from November 2011-April 2013 but had not attended a SSP Clinic (to assess fitness for colonic testing and seek informed consent) or an appointment for colonic testing. These individuals were identified by using the [ScP] in-house database by the Hub Director [INITIALS BLINDED] who extracted episode notes (including free text entries by screening centre staff) for the researchers conducting the medical record review.

Routine [ScP] practice is for two appointment letters to be sent for the SSP clinic. If no contact has been made after this, the screenee is considered a non-attender and the screening episode is closed. Non-participation at colonoscopy is followed by a telephone call (and a letter if non-contactable),

inviting the screenee to re-arrange the appointment; non-response by 14 days precipitates episode closure.

### **Data extraction**

We undertook a detailed medical records review of eligible participants to obtain information about non-attendance. The programme records system is a structured Oracle database (Oracle Corporation, Redwood, CA, USA). Each event within a given screening episode (whether a test result, care decision, or clinical interaction, including telephone consultations) is recorded. Free text entries are encouraged and such notes are kept meticulously by SSPs. These clinical notes constitute a detailed and valuable resource for monitoring and assessing patient behaviour.

To complete the screening records review, the Screening Hub Director [INITIALS BLINDED] reviewed the clinical entries of all eligible patients and extracted the following; (i) screenee age and sex; (ii) point of departure from the screening pathway (i.e. non-attendance at the SSP clinic vs colonoscopy); (iii) previous CRC screening history; (iv) subsequent CRC screening history; and (v) free-text entries recording reasons for non-attendance. Free text entries were made by Screening Centre Staff and summarised conversation with the patient (or their representative) and screening centre staff (either at the SSP clinic or by telephone). To satisfy research governance permissions, the Hub Director excluded participants who had died, left the country/screening centre or refused permission for further contact by the screening programme.

## **Analysis**

These free-text entries were coded by [BLINDED], a psychology researcher; and [BLINDED], a medical practitioner with academic interest in CRC screening. Data were analysed based on established qualitative research methodology<sup>19, 20</sup>. Initially, each researcher independently reviewed and interpreted the free-text data and identified broad categories emerging as reasons for non-attendance (e.g. “unwilling to have test”). Patients were then coded into all categories that were considered to apply to them. The two researchers then harmonised categories and coding by face-to-face discussion. Category names were discussed to determine whether they could be meaningfully merged with others, renamed or separated under distinct headings, or grouped under a broader category heading. The independently-derived codes for each patient were also discussed and any disagreements were resolved in consensus, arbitrated by a third researcher [BLINDED, a psychology researcher] who was blinded to the originally-assigned codes to avoid biasing their decision.

Finally, for each individual subject, the single most important reason for non-attendance was recorded, as judged subjectively in consensus by the raters based on information in the medical records. Data were summarised with descriptive statistics.



## Results

### Characteristics of study population

During the study period, 177,863 individuals were invited for screening across the two centres. 87,664 completed FOBt screening (49.3%) and 2,404 had a positive result (2.7% of those returning a test kit). Records review identified 170 individuals (7.1% of those with a positive result) who ultimately did not undergo colonoscopy prior to screening episode closure (Figure 1 shows routes to episode closure). Of these, 88 individuals (51.8% of all non-attenders) were excluded by the screening hub director prior to data extraction because they had died, left the country, moved to another part of the country or had requested removal of their contact details from the screening programme database, leaving 82 cases for further analysis. No further data were available for the 88 excluded individuals.

Included individuals had a median age of 64.5 years (interquartile range:62.2-69.2 years) and there was an approximately equal gender split (42 females, 40 males). Patients often had a previous history of screening non-adherence: 36 kits had been returned from the 72 previous episodes for which data were available, giving an overall previous gFOBt uptake of 50.0%. About half of all non-attenders did not attend the SSP clinic appointment (38/82,46.3%) and half attended clinic but not colonoscopy (44/82,53.7%).

Patients frequently made repeated telephone contact with screening services, despite ultimately not attending. The median number of times a non-attending screenee was in contact with the screening centre was 2 (IQR:1-4).

Furthermore, family members often also telephoned screening centres on the behalf of the patient; this occurred for 15 of the 82 individuals (18.3%). Most commonly, this was to explain non-attendance. 8 patients (or family members) requested an interpreter (9.8%).

39 individuals had been sent a further FOBt kit by the time of data analysis (i.e. had entered their next biennial round of FOBt screening). Of these, only 17 (43.6%) completed this further round of screening.

### **Reasons for non-participation at screening colonoscopy**

Of the 82 patients, in 66 cases (80.5%) it was possible to extract at least one reason for non-participation from the clinical records. 16 individuals had no relevant information recorded. The remaining 66 individuals had a total of 93 recorded reasons for non-participation, summarised in Table 1.

Most patients had a single recorded reason for non-participation (43/66,65.2%), 18 individuals (27.3%) had 2 recorded reasons and 5 individuals (7.6%) had 3 recorded reasons. Explanations for non-participation fell into seven broad categories: unwillingness to have the test (28/93 reasons,30.1%), other commitments (21/93 stated reasons,22.6%), belief that the FOBt result was a false-positive (16/93 reasons,17.2%), another health issue taking priority (14/93 reasons,15.0%), already having investigation planned elsewhere (7/93 reasons,7.5%); practical barriers (5/93 reasons,5.4%) and patient errors in bowel preparation / dietary restriction

(2/93 reasons,2.2%) (see detailed breakdown of reason categories in Table 1).

Reasons for non-participation were largely similar for either SSP clinic or colonoscopy non-participation, with the exception that SSP clinic non-attenders were more likely to have already arranged colonoscopy outside the programme (SSP non-attenders:5/23 total reasons for non-attendance, 21.7%; Colonoscopy non-participants: 2/70 total reasons,2.9%,  $p=0.0079$ ; Table 1).

When considering only an individual's most important reason for non-participation, similar patterns were demonstrated. 17 of 66 individuals had other commitments (25.8%), 16/66 (24.2%) were unwilling to undergo the test, 13/66 (19.7%) believed the FOBt result was a false-positive, 12/66 (18.2%) patients had another health issue taking priority, 7/66 (10.6%) were planning treatment elsewhere and 1/66 (1.5%) had a practical barrier (e.g. distance to travel, issues with fasting).

### **Author interpretations of free-text data entries**

During interpretation, we noted that many stated reasons for non-attendance were temporary rather than permanent. Examples included short-term illnesses (such as a cold, fever or a problem with medication) or brief trips away, neither of which would preclude colonoscopy at a later date. In these cases, patients may have subsequently forgotten about their appointment. However, some individuals later refused colonoscopy even after a telephone

reminder (e.g. *“patient said she could not come because she's got a bad cold. She was asked if she wanted to rebook. She said she will call when she feels better...[weeks later]...SSP phoned patient to rebook but she does not want to proceed”*; female, 71 years). Another common theme was denial and disbelief that the FOBt result might indicate CRC, and instead must have been a false-positive (e.g. *“Patient opted out – insists results were positive due to a bloody tissue she placed on faeces”*; female, 69 years; *“Patient has piles and is convinced that the bleeding was just due to that”*; female, 69 years).

## **Discussion**

In this study, we retrospectively reviewed medical records of patients who had not completed colonoscopy despite a positive screening FOBt result. We grouped reasons for non-attendance into broad categories; the largest of which were unwillingness to have colonoscopy, other commitments, the belief that the FOBt test result was a false-positive, or other health issues taking priority.

Previous research regarding non-attendance for colonoscopy has often focused on its use as a first-line test<sup>21</sup>. Although this provides information regarding colonoscopy-specific barriers, it does not necessarily apply to a screening programme based on FOBt (or Fecal Immunochemical Testing, FIT), in which patients testing positive are at higher risk of CRC<sup>22, 23</sup>.

Considering FOBt-positive individuals specifically, Shields et al<sup>24</sup> reported on patients in a US municipal opportunistic screening programme: Those with a

positive family history of CRC, greater worry regarding cancer or with a more strongly positive FOBt result were more likely to undergo colonoscopy. Zheng et al<sup>25</sup> found that patients who perceived fewer barriers to screening, greater benefits of screening and had greater knowledge of CRC risk factors reported higher intention to complete screening. More recent data from the Ontario FOBt-based screening programme found that participants with recent prior colonoscopy, hospital admission or having repeat FOBt were less likely to complete colonic testing<sup>11</sup>. Ferrat et al<sup>12</sup> found low socio-economic status was associated with non-completion, as were receiving the FOBt kit via post rather than from a General Practitioner, and inadequate information regarding colonoscopy. Partin et al<sup>14</sup> found that older patients, those with limited life expectancy, and dual diagnosis of psychiatric disorder/substance abuse had higher non-completion rates.

We found that the test itself (colonoscopy) constituted a major barrier to screening completion after positive FOBt. This concurs with recent evidence from a vignette-based study in which 11% of respondents would have declined colonoscopy even if they had symptoms indicating a 10% risk of CRC (similar to after a positive FOBt result)<sup>26</sup>. An appreciable proportion of patients clearly find colonoscopy unappealing, even in the face of a high risk of CRC. Some of these concerns may be alleviated by the offer of alternative tests (e.g. CT colonography), which might be perceived as more acceptable. Data from a Dutch randomised trial suggested that non-attendance at colonoscopy was more likely due to concerns regarding the test, whereas non-attendance at CT colonography was more likely underpinned by lack of

time<sup>27</sup>. US data suggest that non-attenders at colonoscopy would accept an offer of CT colonography<sup>28</sup>, and a small randomised study from Italy found that FOBt-positive patients who declined colonoscopy were more likely to attend when offered CTC than those who were re-offered colonoscopy<sup>29</sup>.

However, altering the test used will not always address fundamental reasons for non-attendance. For example, 16 patients felt there were alternative explanations for their positive FOBt result (including haemorrhoids) or that the result was somehow “incorrect” (e.g. normal previous colonoscopy). Offering an alternative test will not address such misconceptions. Instead, it is important to improve awareness of the principles of CRC screening, particularly with regard to previous colonoscopy (i.e. that a previous normal examination does not always obviate subsequent disease).

Most of the documented reasons for non-completion could have potentially been overcome. For example, temporary fasting or incorrect use of bowel preparation could be resolved by rescheduling. Similarly, while some of the other health issues taking priority were serious, others were not (e.g. temporary medication problems, having a fever or the common cold), and should not prevent colonoscopy at a later date. It is possible that these stated reasons masked true underlying causes. Previous studies have described that patients often present superficial explanations for non-attendance that obscure genuine concerns, such as fear of being diagnosed with cancer<sup>30</sup>. Furthermore, for patients who may already be ambivalent to completing screening, an ostensibly small barrier may become relatively more important

(since that individual may feel there is relatively little to gain by completing screening in any case).

Since many patients in their interactions with the screening centre cited surmountable barriers, it is worth considering how uptake of diagnostic follow-up might be increased. The diverse range of stated reasons for non-attendance means that any single untargeted intervention is unlikely to be successful. Some possible approaches to address the specific barriers we uncovered are shown in Table 2. A “hybrid” approach, with primary care endorsement of a centrally-administered screening process might unify the advantages of both strategies. Such primary care endorsement has been shown to boost FOBt uptake<sup>31</sup> and so it is plausible that it might also be effective for colonoscopy non-attenders. Direct contact with health professionals who can present the case for screening, support informed decision-making, and assist people through the process, may be essential for patients who do not engage initially. US research with “hard-to-reach” groups suggests that so-called “patient navigation” can achieve greater effects compared with those reported for more conventional low-intensity interventions<sup>32</sup>, although a randomised trial of patient navigation in a group of FOBt-positive individuals who did not complete colonic testing failed to show a statistically-significant increase in attendance<sup>33</sup>.

The main strength of this study was the fact that we were able to identify reasons for non-attendance among a particularly difficult-to-access group of individuals, often neglected by prior research. Furthermore, these are patient-

triggered case notes, meaning that the contents likely align with patients' own beliefs. The fact that we found a much smaller proportion of patients who did not complete colonoscopy (7.1%) than has previously been reported, both in the UK<sup>4</sup> and internationally<sup>10,11,30</sup> is likely due to different methods of data extraction and "filtering" of our dataset by the screening Hub Director to ensure patient confidentiality. It is possible that we have not captured some important reasons for non-attendance.

Our study is also limited because we were required to use retrospective reviews of medical records to overcome the difficulties of contacting and interviewing non-adherent patients. Although detailed, it is possible that these medical records do not capture all relevant reasons, and some richness of the dataset will no doubt be lost. Furthermore, the fact that they have been entered by screening staff (rather than patients themselves) means there is a risk of failure to accurately capture the patients' original thoughts or intentions. Although one-to-one interviews are an intuitively appealing alternative, we originally invited patients for a telephone interview to explore their reasons for non-attendance, and received only a 3% response rate – such interviews would be neither representative nor practical. Engagement of non-attenders is clearly extremely challenging, although intense recruitment facilitated via primary care might be possible. Additionally, there was a degree of subjectivity in our assessment and coding process, although we reduced this by using two independent coders and resolving disagreements with a third arbitrator. Our relatively small sample size means the estimated prevalence of each barrier to attendance carries some uncertainty. This could be addressed



by a larger data extraction in the future, allowing more confident estimates of the importance of each of our major categories of reasons for non-attendance. Finally, the screening centres participating in this study are both urban, with relatively higher socio-economic deprivation and ethnic diversity than the national average.

In summary, the most frequently-stated reasons for non-completion of colonoscopy in FOBt-positive patients were unwillingness to have the test, the perception that their FOBt result was a false positive, or other commitments and health issues taking priority. These individuals had low adherence to subsequent FOBt screening, meaning they remain a difficult-to-screen group. Education regarding the nature of FOBt screening and offering alternative tests with flexible scheduling at a range of locations might address some of these concerns.

## **Funding Acknowledgements**

Project-specific and institutional funding acknowledgement statements blinded for review.

## **Declaration of conflicting interests**

The authors have no relevant conflicts of interest.

## References

1. Benson VS, Patnick J, Davies AK, et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. *Int J Cancer*. 2008; 122: 1357-67.
2. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. *Gut*. 2015.
3. Hewitson P, Glasziou P, Irwig L, Towler B and Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. *Cochrane Database Syst Rev*. 2007.
4. Logan RFA, Patnick J, Nickerson C, Coleman L, Rutter MD and von Wagner C. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. *Gut*. 2012; 61: 1439-46.
5. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet*. 1996; 348: 1472-7.
6. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med*. 2000; 343: 1603-7.
7. Kronborg O, Fenger C, Olsen J, Jorgensen OD and Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet*. 1996; 348: 1467-71.
8. Lindholm E, Brevinge H and Haglund E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. *Br J Surg*. 2008; 95: 1029-36.
9. Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. *Br J Cancer*. 2007; 97: 1601-5.
10. Leuraud K, Jezewski-Serra D, Viguier J and Salines E. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. *Cancer Epidemiol*. 2013; 37: 959-67.
11. Correia A, Rabeneck L, Baxter NN, et al. Lack of follow-up colonoscopy after positive FOBT in an organized colorectal cancer screening program is associated with modifiable health care practices. *Prev Med*. 2015; 76: 115-22.
12. Ferrat E, Le Breton J, Veerabudun K, et al. Colorectal cancer screening: factors associated with colonoscopy after a positive faecal occult blood test. *Br J Cancer*. 2013; 109: 1437-44.
13. Kearns B, Whyte S, Seaman HE, et al. Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm. *Br J Cancer*. 2016; 114: 327-33.
14. Partin MR, Gravely A, Gellad ZF, et al. Factors Associated With Missed and Cancelled Colonoscopy Appointments at Veterans Health Administration Facilities. *Clin Gastroenterol Hepatol*. 2016; 14: 259-67.
15. Lyratzopoulos G, Vedsted P and Singh H. Understanding missed opportunities for more timely diagnosis of cancer in symptomatic patients after presentation. *Br J Cancer*. 2015; 112 Suppl 1: S84-91.
16. Carlson CM, Kirby KA, Casadei MA, Partin MR, Kistler CE and Walter LC. Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow up? *Arch Intern Med*. 2011; 171: 249-56.

17. Fisher DA, Jeffreys A, Coffman CJ and Fasanella K. Barriers to full colon evaluation for a positive fecal occult blood test. *Cancer Epidemiol Biomarkers Prev.* 2006; 15: 1232-5.
18. Jimbo M, Myers RE, Meyer B, et al. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. *Ann Fam Med.* 2009; 7: 11-6.
19. Braun V and Clarke V. Using thematic analysis in psychology. *Qualitative research in psychology.* 2006; 3: 77-101.
20. Ritchie J, Spencer L and O'Connor W. Carrying out qualitative analysis. In: Ritchie J and Lewis J, (eds.). *Qualitative Research Practice.* London: SAGE Publications, 2003, p. 219-62.
21. McLachlan S-A, Clements A and Austoker J. Patients' experiences and reported barriers to colonoscopy in the screening context-A systematic review of the literature. *Patient Education and Counseling.* 2011.
22. Felsen CB, Piasecki A, Ferrante JM, Ohman-Strickland PA and Crabtree BF. Colorectal cancer screening among primary care patients: does risk affect screening behavior? *Journal of community health.* 2011; 36: 605-11.
23. Kiviniemi MT, Bennett A, Zaiter M and Marshall JR. Individual-level factors in colorectal cancer screening: a review of the literature on the relation of individual-level health behavior constructs and screening behavior. *Psycho-oncology.* 2011; 20: 1023-33.
24. Shields HM, Weiner MS, Henry DR, et al. Factors that influence the decision to do an adequate evaluation of a patient with a positive stool for occult blood. *The American Journal of Gastroenterology.* 2001; 96: 196-203.
25. Zheng Y-F, Saito T, Takahashi M, Ishibashi T and Kai I. Factors associated with intentions to adhere to colorectal cancer screening follow-up exams. *BMC Public Health.* 2006; 6.
26. Banks J, Hollinghurst S, Bigwood L, Peters TJ, Walter FM and Hamilton W. Preferences for cancer investigation: a vignette-based study of primary-care attendees. *Lancet Oncol.* 2014; 15: 232-40.
27. de Wijkerslooth TR, de Haan MC, Stoop EM, et al. Reasons for participation and nonparticipation in colorectal cancer screening: a randomized trial of colonoscopy and CT colonography. *Am J Gastroenterol.* 2012; 107: 1777-83.
28. Ho W, Broughton DE, Donelan K, Gazelle GS and Hur C. Analysis of barriers to and patients' preferences for CT colonography for colorectal cancer screening in a nonadherent urban population. *AJR Am J Roentgenol.* 2010; 195: 393-7.
29. Sali L, Grazzini G, Ventura L, et al. Computed tomographic colonography in subjects with positive faecal occult blood test refusing optical colonoscopy. *Dig Liver Dis.* 2013; 45: 285-9.
30. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. *J Gen Intern Med.* 2005; 20: 989-95.
31. Hewitson P, Ward AM, Heneghan C, Halloran SP and Mant D. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial. *Br J Cancer.* 2011; 105: 475-80.
32. Paskett ED, Harrop JP and Wells KJ. Patient navigation: an update on the state of the science. *CA Cancer J Clin.* 2011; 61: 237-49.

33. Green BB, Anderson ML, Wang CY, et al. Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial. *J Am Board Fam Med*. 2014; 27: 789-95.